MET and breast cancer: Additionally, platelet RNA signatures helped to distinguish patients with Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), Epidermal Growth Factor Receptor (EGFR) and Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) mutant and wild-type tumors, as well as patients with Human Epidermal Growth Factor Receptor 2 (HER2)-amplified versus HER2-negative breast cancer and Mesenchymal Epithelial Transition tyrosine kinase (MET) overexpressing versus MET non-overexpressing lung cancers [64].